IP Group PLC - Oxford, England-based intellectual property commercialisation - Says portfolio company Autifony Therapeutics Ltd has signed a deal with Jazz Pharmaceuticals PLC worth up to USD770 million for drug discovery and preclinical development on two ion channel targets associated with neurological disorders. Jazz will lead clinical development, manufacturing and regulatory activities and commercialisation once preclinical development is finalised. IP Group holds a 26% stake in Autifony, valued at GBP4.6 million.
Current stock price: 46.55 pence, up 1.9%
12-month change: down 38%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Ip Group (IPO)